Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


USANA expansion

This article was originally published in The Tan Sheet

Executive Summary

Direct marketer's entry into Taiwan slated for Q4. Company putting infrastructure in place and obtaining product approvals, also plans to leverage existing resources in Hong Kong, Australia to support Taiwan entry. One-time costs associated with suspended effort to take direct marketer private result in Q1 earnings per share impact of 3¢, USANA says April 25. Nevertheless, net earnings rose 140% from year-ago quarter to $1.1 mil. on a 3.7% sales gain to $28.6 mil. Improved margins resulted from production efficiencies, adjustment in pricing strategy, firm explains. USANA founder Myron Wentz cited company's improved performance as reason for terminating his bid to take it private (1"The Tan Sheet" April 15, 2002, p. 5)...

You may also be interested in...


Projected fourth quarter net sales of more than $37 mil. would be firm's highest quarterly revenues ever, Salt Lake City-based supplement direct seller says Dec. 18. Stronger-than-expected results were driven by "an increased number of associate enrollments, spurred by the newly launched Taiwan market and continued growth in each of our major markets," USANA states. Firm announced plan to enter Taiwan earlier this year (1"The Tan Sheet" May 13, 2002, In Brief)...

Herbalife Buyout By Equity Groups Achieves Long-Sought Private Ownership

The pending acquisition of Herbalife by equity firms Whitney & Co. and Golden Gate Capital ends a two-and-a-half year effort, initiated by late founder and CEO Mark Hughes, to take the direct marketer private

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts